How do you incorporate surveillance imaging for patients with ovarian cancer on maintenance therapy?
Does your strategy differ if the patient is on maintenance PARP inhibitor, bevacizumab, both, or neither?
1 Answer
Mednet MemberInvited Expert
Gynecologic Oncology · Cooper Medical School of Rowan University
Answered on
I typically follow the NCCN guidelines for monitoring/follow up:
- Visit every 3 months for 2 years, then every 3-6 months for 3 years, then yearly after year 5.
- CA125 (or other tumor markers) at each visit if initially elevated (with the understanding that CA125 monitoring does not affect survival, ...
Join for free or sign in to see the full answer